Literature DB >> 11107142

Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents.

P E Lovat1, M Ranalli, F Bernassola, M Tilby, A J Malcolm, A D Pearson, M Piacentini, G Melino, C P Redfern.   

Abstract

The RARbeta/gamma-selective retinoids fenretinide and CD437 induce caspase-dependent apoptosis but generate free radicals independently of caspases. Apoptosis, but not free radical generation, induced by these retinoids is inhibited by RARbeta/gamma-specific antagonists. Both fenretinide and CD437 induce apoptosis synergistically with cisplatin, carboplatin, or etoposide. However, antioxidants inhibit this synergy to the level obtained with chemotherapeutic drugs alone, and this implies that free radical generation is important in the synergistic response. Since apoptosis induced by fenretinide or CD437 is mediated by apoptotic pathways involving RARs and/or mitochondria and differs from mechanisms of chemotherapy-induced apoptosis this may explain the strong synergistic response seen between these synthetic retinoids and chemotherapeutic drugs. These results suggest that fenretinide or CD437 may be useful adjuncts to neuroblastoma therapy. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11107142     DOI: 10.1002/1096-911x(20001201)35:6<663::aid-mpo39>3.0.co;2-4

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  2 in total

1.  Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling.

Authors:  Yanzhi Du; Yuan Xia; Xiaoling Pan; Zi Chen; Aihua Wang; Kankan Wang; Junmin Li; Ji Zhang
Journal:  Antioxid Redox Signal       Date:  2013-10-24       Impact factor: 8.401

2.  Fenretinide targeting of human colon cancer sphere cells through cell cycle regulation and stress-responsive activities.

Authors:  Lanlan Liu; Jiansheng Liu; Haiwei Wang; Hui Zhao; Yanzhi Du
Journal:  Oncol Lett       Date:  2018-08-13       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.